Taipei Exchange - Delayed Quote TWD

Mycenax Biotech Inc. (4726.TWO)

37.85
+1.80
+(4.99%)
At close: 1:10:35 PM GMT+8
Loading Chart for 4726.TWO
  • Previous Close 36.05
  • Open 36.20
  • Bid 37.85 x --
  • Ask 37.90 x --
  • Day's Range 35.60 - 37.95
  • 52 Week Range 27.40 - 65.20
  • Volume 487,321
  • Avg. Volume 251,264
  • Market Cap (intraday) 7.854B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.23
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

www.mycenax.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4726.TWO

View More

Performance Overview: 4726.TWO

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4726.TWO
12.79%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
6.03%

1-Year Return

4726.TWO
12.49%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.44%

3-Year Return

4726.TWO
5.58%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
34.08%

5-Year Return

4726.TWO
17.91%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.23%

Compare To: 4726.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4726.TWO

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    7.48B

  • Enterprise Value

    8.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.27

  • Price/Book (mrq)

    3.94

  • Enterprise Value/Revenue

    11.30

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -63.50%

  • Return on Assets (ttm)

    -8.38%

  • Return on Equity (ttm)

    -21.85%

  • Revenue (ttm)

    725.45M

  • Net Income Avi to Common (ttm)

    -460.65M

  • Diluted EPS (ttm)

    -2.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    273.93M

  • Total Debt/Equity (mrq)

    41.85%

  • Levered Free Cash Flow (ttm)

    118.43M

Research Analysis: 4726.TWO

View More

Company Insights: 4726.TWO

Research Reports: 4726.TWO

View More

People Also Watch